Abstract
The association between type 2 diabetes mellitus (T2DM) and systemic inflammation may increase platelet reactivity and the accelerated development of vascular disease. Platelets are able to modulate the function of immune cells via the direct release of growth factors and pro-inflammatory chemokines through the production of microvesicles. The microvesicles trigger a transcellular delivery system of bioactive molecules to other cells acting as vectors in the exchange of biological information. Here, we consider the influence of platelets and platelet-derived microvesicles on cells of the immune system and the implications in the pathogenesis of T2DM.
Keywords: Platelets, microvesicles, immune, effectors, diabetes, inflammation.
Graphical Abstract
Current Vascular Pharmacology
Title:Platelets and Platelet-Derived Microvesicles as Immune Effectors in Type 2 Diabetes
Volume: 15 Issue: 3
Author(s): Nancy Cortez-Espinosa, Laura Perez-Campos Mayoral*, Eduardo Perez-Campos, Hector Alejandro Cabrera Fuentes, Eduardo Perez-Campos Mayoral, Ruth Martínez-Cruz, Socorro Pina Canseco, Gabriel Mayoral Andrade, Margarito Martinez Cruz, Itandehui Gallegos Velasco and Pedro Hernandez Cruz
Affiliation:
- Department of Investigation Medicine-UNAM-UABJO, Faculty of School of Medicine, UABJO University, CP 60120, Oaxaca,Mexico
Keywords: Platelets, microvesicles, immune, effectors, diabetes, inflammation.
Abstract: The association between type 2 diabetes mellitus (T2DM) and systemic inflammation may increase platelet reactivity and the accelerated development of vascular disease. Platelets are able to modulate the function of immune cells via the direct release of growth factors and pro-inflammatory chemokines through the production of microvesicles. The microvesicles trigger a transcellular delivery system of bioactive molecules to other cells acting as vectors in the exchange of biological information. Here, we consider the influence of platelets and platelet-derived microvesicles on cells of the immune system and the implications in the pathogenesis of T2DM.
Export Options
About this article
Cite this article as:
Cortez-Espinosa Nancy, Mayoral Perez-Campos Laura*, Perez-Campos Eduardo, Cabrera Fuentes Alejandro Hector, Mayoral Perez-Campos Eduardo, Martínez-Cruz Ruth, Canseco Pina Socorro, Andrade Mayoral Gabriel, Cruz Martinez Margarito, Velasco Gallegos Itandehui and Cruz Hernandez Pedro, Platelets and Platelet-Derived Microvesicles as Immune Effectors in Type 2 Diabetes, Current Vascular Pharmacology 2017; 15 (3) . https://dx.doi.org/10.2174/1570161115666170126130309
DOI https://dx.doi.org/10.2174/1570161115666170126130309 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Interaction studies of Withania somnifera’s key metabolite Withaferin A with different receptors associated with cardiovascular disease
Current Computer-Aided Drug Design Association of Selected Adipocytokines and Inflammatory Markers on Body Mass Index in Type 2 Diabetes Patients in Saudi Arabia and as Risk Factors to Cardiovascular Disease
Current Diabetes Reviews Aliskiren, a Direct Renin Inhibitor, in Clinical Practice: A New Approach in the Treatment of Hypertension
Current Vascular Pharmacology Determination of Body Mass Index and Physical Activity in Normal Weight Children and Evaluation of Salivary Levels of Interleukin 10 and Interleukin 17
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Free Radicals in Living Systems: In Vivo Detection of Bioradicals with EPR Spectroscopy
Current Organic Chemistry Electrocardiographic and Cardiac Autonomic Indices - Implications of Sex-Specific Risk Stratification in Women After Acute Myocardial Infarction
Current Pharmaceutical Design Fatty Acid (FA) Compositions and Trans Content of Frequently Consumed Edible Oils and Fats from Iran’ Market
Current Nutrition & Food Science Applications of Nucleic Acid Drugs for Organ Transplantation
Current Topics in Medicinal Chemistry Advancement in Obesity Management: Leptin and Adiponectin Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Development of a Suitable Dissolution Method for the Combined Tablet Formulation of Atorvastatin and Ezetimibe by RP-LC Method
Current Drug Delivery Understanding the Diverse Needs of Children Whose Parents Abuse Substances
Current Drug Abuse Reviews NADPH Oxidases and Inflammatory Bowel Disease
Current Medicinal Chemistry Endothelial Dysfunction in Diabetes: The Role of Protein Kinase C
Vascular Disease Prevention (Discontinued) Role of Asymmetric Dimethylarginine in Cardiorenal Syndrome
Current Pharmaceutical Design The Effects of Obesity-Related Peptides on the Vasculature
Current Vascular Pharmacology Molecular Markers of Cardiovascular Damage in Hypertension
Current Pharmaceutical Design Ethnopharmacological and Phytopharmaceutical Evaluation of Prosopis cineraria: An Overview and Future Prospects
Current Drug Metabolism Editorial (Thematic Issue: New Technological and Clinical Trends in Blood Pressure Theranostics: Is it Time to Consider a Spatio-Temporal Approach?)
Current Pharmaceutical Design Therapeutical Potential of CB<sub>2</sub> Receptors in Immune-Related Diseases
Current Molecular Pharmacology Impact of the CD40-CD40L Dyad in Alzheimers Disease
CNS & Neurological Disorders - Drug Targets